Calcivis, a Edinburgh, Scotland, UK-based medical devices company, secured £4.5m in new equity and grant funding.
Backers included Archangel Investors and the Scottish Investment Bank, have invested a further £2.6m while the company has also secured €2.6m (£1.9m) in grant funding from the European Commission under its Horizon 2020 SME Instrument programme.
The new funding will be used to further prepare the Calcivis® Caries Activity Imaging System for commercialization.
The system is an in-clinic device which combines a sensitive intraoral camera and application technology to deliver a precise amount of proprietary disclosing solution, containing a photoprotein, onto the tooth surface.
The device has a CE Mark in Europe and Calcivis recently reported that a first clinical study met its primary performance endpoint relating to the System’s ability to identify early active caries lesions.
Led by Adam Christie, CEO, Calcivis is now undertaking further work to prepare for commercialization in Europe and to gain approval to market the product in the US.